Bavituximab

Drug Profile

Bavituximab

Alternative Names: 3G4; Anti-phosphatidylserine monoclonal antibody 3G4; Anti-phospholipid monoclonal antibody 3G4; Anti-PS MAb 3G4; Monoclonal antibody 3G4; Tarvacin

Latest Information Update: 04 Nov 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Peregrine Pharmaceuticals; University of Texas M. D. Anderson Cancer Center
  • Developer H. Lee Moffitt Cancer Center and Research Institute; Immunovaccine; Massachusetts General Hospital; National Comprehensive Cancer Network; Peregrine Pharmaceuticals; University of Arizona; University of Texas Southwestern Medical Center
  • Class Adjuvants; Antineoplastics; Antivirals; Monoclonal antibodies
  • Mechanism of Action Angiogenesis inhibitors; Immunostimulants; Phosphatidylserine receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • Phase III Non-small cell lung cancer
  • Phase II Glioblastoma
  • Phase I/II Hepatocellular carcinoma
  • Preclinical Solid tumours
  • Suspended Breast cancer; Malignant melanoma; Pancreatic cancer; Rectal cancer
  • No development reported Brain cancer; Hepatitis C; HIV infections; Viral haemorrhagic fevers
  • Discontinued Influenza virus infections; Prostate cancer

Most Recent Events

  • 04 Nov 2017 No recent reports of development identified for preclinical development in Brain-cancer in USA (IV, Infusion)
  • 11 Sep 2017 Efficacy data from a subgroup analysis of the phase III SUNRISE trial in Non small cell lung cancer presented at the 42nd European Society of Medical Oncology (ESMO-2017)
  • 08 Sep 2017 Adverse events data from the phase III SUNRISE trial in Non small cell lung cancer presented at the 42nd European Society of Medical Oncology (ESMO-2017)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top